Johnson Nancy JoAnn sold $100K of BLLN

Johnson Nancy JoAnn (See Remarks) sold 801 shares of BillionToOne, Inc. (BLLN) at $124.91 ($0.10M total) on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Johnson Nancy JoAnn
Published Jul 7, 2026, 12:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 7, 2026, 1:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
high confidence
Mentioned
$BLLN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The disclosed fact is an open-market sale of 801 shares at a stated price, with holdings after the transaction and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental catalyst in the text.

03

What to watch

The article lacks context on total planned sales, whether this tranche is part of a larger schedule, and whether there were concurrent insider buys—so sentiment impact should be discounted.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-06 for a 2026-07-01 sale

Background

The article is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralHigh confidence
Context

SEC Form 4 shows officer Nancy JoAnn Johnson sold 801 shares of BillionToOne at $124.9137 on 2026-07-01 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven.

Evidence & confidence

The filing is an open-market sale with an explicitly stated pre-arranged Rule 10b5-1 plan, and the article provides no new operating, regulatory, or financial datapoints.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild caution signal, especially if paired with other negative news (not present here).

Key entities

  • BillionToOne, Inc.

    Subject of the Form 4 insider transaction; officer Nancy JoAnn Johnson sold shares under a 10b5-1 plan.

  • Nancy JoAnn Johnson

    Officer who executed the reported open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.